~~<i id='C12024C132'><strike id='C12024C132'><tt id='C12024C132'><pre id='C12024C132'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：fashion 2025-10-06 16:00:57 Page View：8

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Why some fertility treatments produce more boy babies
Next article： Alkermes shareholders re

leisure time

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Medical students need to learn the potent medicine of empathy

JoeRaedle/GettyImagesAfewyearsagoatalargeteachinghospitalinTexas,amedicalresidentaskedanursehowtoord

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

1 in 4 Americans hadn't contracted COVID by the end of 2022, CDC estimates

0:53Shoppers,somewearingmasks,visitinamarket,July14,2022inLosAngeles,duringtheCOVID-19pandemic.LosAn

WSS

knowledge

knowledge

focus

leisure time

1 in 4 Americans hadn't contracted COVID by the end of 2022, CDC estimates